Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3830984 | 0.87 | NPC1 (0.40) | KDM4EALDH1A1KIF11PDGFRBKDR | |
| SCHEMBL3217246 | 0.85 | KDM4E (0.35) | KDM4EALDH1A1KIF11PDGFRBKDR | |
| SCHEMBL9885138 | 0.83 | ALDH1A1 (0.36) | KDM4EALDH1A1KIF11PDGFRBKDR | |
| SCHEMBL3834575 | 0.83 | PDGFRB (0.36) | KDM4EALDH1A1KIF11PDGFRBKDR | |
| SCHEMBL3209318 | 0.83 | PDGFRB (0.45) | KDM4EALDH1A1KIF11PDGFRBKDR | |
| SCHEMBL3832900 | 0.81 | KDM4E (0.34) | KDM4EALDH1A1KIF11PDGFRBKDR | |
| SCHEMBL3835634 | 0.81 | ALDH1A1 (0.40) | KDM4EALDH1A1PDGFRBKDRNR3C2 | |
| SCHEMBL3205898 | 0.81 | PARP1 (0.40) | KDM4EALDH1A1KIF11PDGFRBKDR | |
| SCHEMBL3835837 | 0.81 | PARP1 (0.40) | KDM4EALDH1A1KIF11PDGFRBKDR | |
| SCHEMBL3219057 | 0.81 | GSK3B (0.37) | KDM4EALDH1A1KIF11PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | NFKBIA, IKBKB, IKBKG | KDM4E 1670/4885ALDH1A1 3077/4885EPHX1 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.